Начало・Списък с акции・Natera Inc

Natera Inc

Затворен

СекторЗдравеопазване

264.36 -3.66

Купи Продай

Преглед

Промяна на цената на акция

24 ч

Текуща

Минимум

262.72

Максимум

272.82

Ключови измерители
By Trading Economics
Приходи	-132M -85M
Продажби	31M 697M
EPS	-0.6
Марж на печалбата	-12.214
Служители	6,135
EBITDA	-30M -65M

Препоръки
By TipRanks
Препоръки	Силна покупка
12-месечна прогноза	+7.96% upside

Дивиденти
By Acuity
Следващи печалби	5.11.2026 г.

Пазарни показатели
By TradingEconomics
Пазарна капитализация	8.5B 39B
Предишно отваряне	268.02
Предишно затваряне	264.36

Настроения в новините

By Acuity

38%

62%

131 / 340 Класиране в Healthcare

Natera Inc Графика

Миналото представяне не гарантира бъдещи резултати.

Свързани новини

6.08.2026 г., 23:02 ч. UTC

Social Media

News

Natera Inc reported second-quarter revenue of $752.8 million, exceeding expectations. The stock is trading higher after the market closed, following strong earnings results.

5.08.2026 г., 23:01 ч. UTC

Event

Natera Inc announced an application for the Signatera test in Japan. Shares are trading lower in after-market hours following the announcement.

4.08.2026 г., 19:04 ч. UTC

Natera Inc shares are rising amid a broader market rally and high trading volume, despite challenges from declining U.S. factory orders and falling oil prices.

3.08.2026 г., 19:23 ч. UTC

News

Natera Inc. shares are higher today, reflecting broader market gains amid strong manufacturing data and significant increases in major technology stocks.

31.07.2026 г., 19:46 ч. UTC

Social Media

Natera Inc shares are lower today, reflecting broader declines in the genomic sector despite earlier gains and a rebound through key moving averages.

30.07.2026 г., 17:51 ч. UTC

News

Citi initiated coverage of Natera Inc with a Buy rating and a $300 price target, contributing to the stock's upward movement today.

29.07.2026 г., 22:02 ч. UTC

Natera Inc. shares declined in after-market trading, reversing an initial uptick. The stock is below its 20-day moving average amid cautious market sentiment.

28.07.2026 г., 23:46 ч. UTC

Natera Inc shares are higher in after-market hours, showing positive momentum despite remaining below their 20-day moving average after recent declines.

27.07.2026 г., 19:46 ч. UTC

News

Natera Inc's shares are lower today, reflecting broader market trends amid a significant drop in crude oil prices affecting sentiment across sectors.

24.07.2026 г., 18:46 ч. UTC

News

Natera Inc's shares are lower, retracing from earlier highs amid broader market dynamics and a drop in oil prices affecting various sectors.

22.07.2026 г., 18:36 ч. UTC

News

Natera Inc shares are lower following a JAMA study showing its Signatera test's effectiveness for Merkel cell carcinoma, despite favorable sensitivity results.

21.07.2026 г., 18:36 ч. UTC

Natera Inc shares are higher, reflecting positive sentiment in U.S. markets amid strong earnings from companies like General Motors and Novartis.

20.07.2026 г., 18:16 ч. UTC

News

Natera Inc. shares are lower today, despite positive developments expanding access to its Prospera transplant test and increased revenue from higher testing volumes.

Сравнение с други в отрасъла

Ценова промяна

Natera Inc Прогноза

Ценова цел

By TipRanks

7.96% нагоре

12-месечна прогноза

Среден 286.5 USD 7.96%

Висок 340 USD

Нисък 220 USD

Според 19 анализатори от Wall Street, предложили 12-месечна ценова цел за Natera Inc през последните три месеца.

Консенсусна оценка

By TipRanks

Силна покупка

19 ratings

Купи

Задържане

Продай

Според 19 анализатори, дали борсови рейтинги на Natera Inc през последните 3 месеца.

Настроение

By Acuity

131 / 340 Класиране в Здравеопазване

Финанси

Продажбени и админисративни разходи

Оперативни разходи

Печалба преди облагане с данъци

Продажби

Разходи за продажби

Брутна печалба от продажби

Разходи за лихви по дълг

EBITDA

Оперативна печалба

Относно Natera Inc

Natera, Inc., a diagnostics company, develops and commercializes molecular testing services worldwide. Its products include Panorama, a non-invasive prenatal test that screens for chromosomal abnormalities of a fetus, as well as in twin pregnancies; Horizon carrier screening test for individuals and couples determine if they are carriers of genetic variations that cause certain genetic conditions; Vistara single-gene NIPT screens for 25 single-gene disorders that cause severe skeletal, cardiac, and neurological conditions; Spectrum, preimplantation genetic tests for couples undergoing IVF; Anora that analyzes miscarriage tissue from women; Empower, a hereditary cancer screening test; and non-invasive prenatal paternity product, which allows a couple to establish paternity without waiting for the child to be born. The company also provides Signatera, a ctDNA blood test for molecular residual disease assessment and surveillance of disease recurrence in patients previously diagnosed with cancer; Altera, a tissue based comprehensive genomic profiling test; Prospera to assess active rejection in patients who have undergone kidney, heart, and lung transplantation; and Renasight, a kidney gene panel test. In addition, it offers Constellation, a cloud-based software product that enables laboratory customers to gain access through the cloud to the company's algorithms and bioinformatics to validate and launch tests. The company offers products through its direct sales force, as well as through a network of laboratory and distribution partners. It has a partnership agreement with BGI Genomics Co., Ltd. to develop, manufacture, and commercialize NGS-based genetic testing assays; and Foundation Medicine, Inc. to develop and commercialize personalized circulating tumor DNA monitoring assays. The company was founded in 2003 and is headquartered in Austin, Texas.